NO125455B - - Google Patents
Download PDFInfo
- Publication number
- NO125455B NO125455B NO1734/68A NO173468A NO125455B NO 125455 B NO125455 B NO 125455B NO 1734/68 A NO1734/68 A NO 1734/68A NO 173468 A NO173468 A NO 173468A NO 125455 B NO125455 B NO 125455B
- Authority
- NO
- Norway
- Prior art keywords
- tetanus
- toxoid
- tetanus toxoid
- pepsin
- product
- Prior art date
Links
- 229960000814 tetanus toxoid Drugs 0.000 description 16
- 239000000047 product Substances 0.000 description 14
- 102000057297 Pepsin A Human genes 0.000 description 10
- 108090000284 Pepsin A Proteins 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 229940111202 pepsin Drugs 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 239000004202 carbamide Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010043376 Tetanus Diseases 0.000 description 6
- 229960002766 tetanus vaccines Drugs 0.000 description 6
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 5
- 241000700198 Cavia Species 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 5
- 108010000912 Egg Proteins Proteins 0.000 description 5
- 235000014103 egg white Nutrition 0.000 description 5
- 210000000969 egg white Anatomy 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1967B0092391 DE1617344B2 (de) | 1967-05-06 | 1967-05-06 | Verfahren zur herstellung eines tetanus-impfstoffes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO125455B true NO125455B (uk) | 1972-09-11 |
Family
ID=6986370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO1734/68A NO125455B (uk) | 1967-05-06 | 1968-05-03 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US3542920A (uk) |
| AT (1) | AT277460B (uk) |
| BE (1) | BE714696A (uk) |
| CH (1) | CH513653A (uk) |
| DE (1) | DE1617344B2 (uk) |
| DK (1) | DK119939B (uk) |
| ES (1) | ES353533A1 (uk) |
| FI (1) | FI45765C (uk) |
| FR (1) | FR7913M (uk) |
| GB (1) | GB1229988A (uk) |
| IE (1) | IE32044B1 (uk) |
| IL (1) | IL29925A (uk) |
| LU (1) | LU56019A1 (uk) |
| NL (1) | NL157803B (uk) |
| NO (1) | NO125455B (uk) |
| SE (1) | SE341984B (uk) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2340911A1 (de) * | 1973-08-13 | 1975-05-07 | Behringwerke Ag | Tetanus-antigen und verfahren zu seiner herstellung |
| DE2355094C3 (de) * | 1973-11-03 | 1979-05-23 | Behringwerke Ag, 3550 Marburg | Verfahren zur Herstellung eines Tetanus-Impfstoffs |
| DE2510987C2 (de) * | 1974-10-29 | 1983-03-24 | Behringwerke Ag, 3550 Marburg | Verfahren zur Herstellung eines Tetanusimpfstoffes |
| DE2457047C3 (de) * | 1974-12-03 | 1979-10-31 | Behringwerke Ag, 3550 Marburg | Verfahren zur Herstellung eines Derivates der leichten Kette des Tetanustoxins, dessen Verwendung zur Tetanusprophylaxe |
| JPH06192118A (ja) * | 1992-09-28 | 1994-07-12 | Wisconsin Alumni Res Found | ボツリヌス毒素を含む異常に過敏な筋運動障害の治療用薬剤組成物およびその製造方法 |
-
1967
- 1967-05-06 DE DE1967B0092391 patent/DE1617344B2/de active Granted
-
1968
- 1968-04-30 US US725525A patent/US3542920A/en not_active Expired - Lifetime
- 1968-04-30 FI FI681232A patent/FI45765C/fi active
- 1968-04-30 IE IE505/68A patent/IE32044B1/xx unknown
- 1968-05-01 NL NL6806143.A patent/NL157803B/xx not_active IP Right Cessation
- 1968-05-03 NO NO1734/68A patent/NO125455B/no unknown
- 1968-05-03 LU LU56019D patent/LU56019A1/xx unknown
- 1968-05-03 IL IL29925A patent/IL29925A/en unknown
- 1968-05-03 DK DK206668AA patent/DK119939B/da unknown
- 1968-05-03 AT AT428068A patent/AT277460B/de not_active IP Right Cessation
- 1968-05-03 CH CH656568A patent/CH513653A/de not_active IP Right Cessation
- 1968-05-06 SE SE6050/68A patent/SE341984B/xx unknown
- 1968-05-06 GB GB1229988D patent/GB1229988A/en not_active Expired
- 1968-05-06 BE BE714696D patent/BE714696A/xx unknown
- 1968-08-05 FR FR161922A patent/FR7913M/fr not_active Expired
-
1969
- 1969-05-04 ES ES353533A patent/ES353533A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FI45765C (fi) | 1972-09-11 |
| LU56019A1 (uk) | 1970-01-13 |
| IE32044B1 (en) | 1973-03-21 |
| FI45765B (uk) | 1972-05-31 |
| DK119939B (da) | 1971-03-15 |
| GB1229988A (uk) | 1971-04-28 |
| CH513653A (de) | 1971-10-15 |
| NL6806143A (uk) | 1968-11-07 |
| ES353533A1 (es) | 1970-01-16 |
| AT277460B (de) | 1969-12-29 |
| FR7913M (uk) | 1970-05-11 |
| NL157803B (nl) | 1978-09-15 |
| BE714696A (uk) | 1968-11-06 |
| DE1617344A1 (de) | 1971-03-25 |
| IL29925A0 (en) | 1968-07-25 |
| IE32044L (en) | 1968-11-06 |
| DE1617344B2 (de) | 1976-04-08 |
| SE341984B (uk) | 1972-01-24 |
| US3542920A (en) | 1970-11-24 |
| IL29925A (en) | 1972-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4459286A (en) | Coupled H. influenzae type B vaccine | |
| Lancefield et al. | Type-specific polysaccharide antigens of group B streptococci | |
| Beachey et al. | Purification and properties of M protein extracted from group A streptococci with pepsin: covalent structure of the amino terminal region of type 24 M antigen | |
| Morse | Isolation and properties of a surface antigen of Staphylococcus aureus | |
| Jansen | The toxic antigenic factors produced by Clostridium botulinum types C and D | |
| US4207414A (en) | Polysaccharide antigens | |
| US4324887A (en) | Type II group B Streptococci polysaccharide | |
| Moran et al. | Chemical Modification of Crude Timothy Grass Pollen Extract: I. Antigenicity and Immunogenicity Changes following Amino Group Modification | |
| NO125455B (uk) | ||
| US3674863A (en) | Polyvalent immunizing agents and methods for their production | |
| US4367222A (en) | Immune globulin specific to Group B streptococci | |
| IE42760B1 (en) | Derivatives of the tetanus toxin, process for their preparation and agents containing them | |
| US4356263A (en) | Method of making a polysaccharide vaccine | |
| Schmidt et al. | Immunodiffusion reactions with rubella antigens | |
| US4367223A (en) | Vaccine against Group B streptococci | |
| US4367221A (en) | Immunization against Group B streptococci | |
| Dubos | The effect of formaldehyde on pneumococci | |
| DK143249B (da) | Fremgangsmaade til fremstilling af en vandig gamma-globulinoploesning til terapeutisk anvendelse mod infektioner af pseudomonas aeruginosa | |
| Yohn et al. | EGHO-4 Viruses: Improved Methods and Strain Selection for Identification and Serodiagnosis | |
| Kane et al. | Existence of multiple immunodeterminants in the type-specific capsular substance of group B type Ia streptococci | |
| Panse et al. | Passive immunity in experimental cholera | |
| US2405740A (en) | Agglutinogen derived from whooping cough organisms | |
| Smadel et al. | INFECTIOUS MYXOMATOSIS OF RABBITS: II. Demonstration of a Second Soluble Antigen Associated with the Disease | |
| Seal et al. | Studies on the purification of alum-precipitated diphtheria toxoid | |
| Keppie et al. | The chemical basis of the virulence of Pasteurella pestis. III. An immunogenic product obtained from Past. pestis which protects both guinea-pigs and mice. |